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Clin Transplant. 
 
Abstract 
The aim of the present study was to investigate association of serum amino (AA) acids 
and metabolites of AAs with post-transplant outcome in liver transplant recipients.  
Eighty-nine patients with end-stage liver diseases and available pre- and early post-
transplant serum were characterised as patients with (GI) and without one-year mor-
tality (GII) and patients with and without early graft dysfunction (EAD). A panel of pre- 
and early post-transplant serum levels of AAs and early and metabolites of tryptophan 
were measured using tandem mass spectrometry.  
Patient groups had significantly higher pre-transplant serum levels of phenylalanine, 
tryptophan, and tryptophan metabolites than healthy controls (for all p<0.001). Pre-
transplant serum levels of all these parameters were significantly higher in GI than in 
GII (for all p<0.001). GI had a higher MELD score and re-transplantation number than 
GII (p≤0.005 for both investigations). Serum bilirubin on day 5 and serum phenyla-
lanine on day 10 post-transplant were associated parameters of mortality, whereas 
day 1post-transplant phenylalanine and kynurenine and female gender were associ-
ated parameters of EAD.  
Our results indicate that pre- and early post-transplant levels of phenylalanine, trypto-
phan and metabolites of tryptophan are increased in patients and are associated with 
EAD and one-year mortality in liver transplant recipients. 
 
Key words: tryptophan, kynurenine, kynurenic acid, phenylalanine, MELD 
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ABREVIATIONS 
CMV: Cytomegalovirus 
CRP: C-reactive protein 
EAD: Early graft dysfunction 
ESLD: End-stage liver diseases 
HBV: Hepatitis B virus 
HCV: Hepatitis C virus 
HIV: Human immunodeficiency virus 
IDO: indoleamine 2,3-dioxygenase  
IFN: Interferon 
MELD: Model for End-Stage Liver Disease 
NPV: Negative predictive value 
PPV: Positive predictive value 
ROC: Receiver operating characteristic 
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Post-transplant outcome in adult liver transplant recipients is associated with pre-, 
peri- and post-transplant risk factors including Model for End-Stage Liver Disease 
(MELD) score (1), pre-transplant nutritional status (2), pre- (3) and post-transplant kid-
ney (4) and heart (4) disease, post-transplant infection (5), and venous thrombosis (6). 
A multivariate analysis by McDiarmid et al. indicated that vascular thrombosis, bowel 
perforation, septicemia, and re-transplantation, each independently increased the risk 
of patient and graft loss by 3 to 4 fold during the first 6 post-transplant months (7). Sun 
et al. identified MELD score >30, Intensive Care Unit stay >48 h prior to transplanta-
tion, intra-operative transfusion ≥15 units, re-transplantation, post-transplant dialysis, 
or reoperation as risk factors for infection during the first 3 post-transplant months (8).  
AAs have direct or indirect inflammatory, anti-inflammatory and immunomodulatory 
effects. Recently, we reported on an association of phenylalanine and tryptophan me-
tabolites with activated cytomegalovirus (CMV) infection in kidney transplant recipients 
(9) and pre-transplant plasma kynurenine as a predictor of acute rejection in kidney 
transplant recipients (10). Almost all published research on the kynurenine pathway is 
restricted to inflammatory responses to nervous system (11) diseases. Indoleamine 
2,3-dioxygenase (IDO) degrades the essential AA tryptophan into kynurenine and 
other downstream metabolites that suppress effector T-cell function (12) and favor the 
differentiation of regulatory T cells (13). IDO is widely distributed in mammals and is 
inducible preferentially by interferon (IFN)- (14). IDO is traditionally regarded as a 
general suppressor of T-cell activation and mediator of immune escape in cancer (13). 
Recently, evidence has emerged to support a greater functional complexity of IDO1 as 
modifier of pathogenic inflammation (13). For instance, IDO1 activity may sustain 
autoantibody production by B cells, and elicit the development of cancer in the context 
of chronic inflammation (13). Studying an old population, Capuron et al. showed that 
increased inflammation was related to reduced tryptophan concentrations and in-
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creased kynurenine levels. In the study by Capuron, inflammation was associated with 
increases in phenylalanine concentrations (15). In a recent study we reported on as-
sociation of plasma quinolinic acid and severity of hepatic dysfunction in patients with 
liver cirrhosis (16). The results showed that quinolinic acid and neopterin are more 
sensitive markers for severity of liver disease than established markers of inflamma-
tion such as C-reactive protein (CRP), and IL-6 and that quinolinic acid provided the 
most sensitive index with regard to the identification of patients with hepatic encepha-
lopathy (16). We also reported on an association of early post-transplant neopterin 
(IFN--dependent response) and one-year patient survival and bacteremia in liver 
transplant recipients (17). Associations of pre- and early post-transplant serum AAs 
and their metabolites with recipient outcome in liver transplantation have not been 
studied. In the present study, we investigated whether pre-transplant serum AA and 
AA metabolites -especially the IFN--dependent kynurenine pathway, among other risk 
factors, are associated with recipient survival in liver transplant recipients.  
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Material and Methods 
Characteristics of the study population 
The retrospective study was conducted in accordance with local ethical guidelines and 
all individuals gave informed consent for the analysis of their plasma samples. Be-
tween January 2008 and April 2010, 178 patients underwent liver transplantation at 
the university hospital Heidelberg, Germany. Pre- and early post-transplant concentra-
tions of all essential amino acids including tryptophan and phenylalanine and metabo-
lites of tryptophan such as  kynurenine, kynurenic acid and quinolinic acid were meas-
ured in available serum samples of 89 adult (age 52.2  10.6 years; 23 female) pa-
tients. Patients showed different disease severity based on MELD staging. Fifty pa-
tients experienced first bacterial infections including urinary tract infection, blood 
stream infection, pneumonia, wound infection and cholangitis during 2931 days post-
transplant. Sixteen patients (8.9% of all patients and 18% of the study group, GI) died 
during one-year post-transplant due to graft failure and sepsis, whereas 73 patients 
survived more than one year and were considered as age- and gender-matched pa-
tients (GII). Patients who died due to sepsis had similar demographic and mortality risk 
factors as patients who died by graft failure. Twenty-one patients experienced early 
allograft dysfunction (EAD). 
The transplantation was due to liver failure caused by chronic viral hepatitis C and/or B 
in 28 patients, alcohol abuse in 28, congenital or autoimmune disease including cryp-
togenic cirrhosis, biliary disease, metabolic liver disease, autoimmune hepatitis and 
amyloidosis in 28 patients. Five patients experienced acute toxic hepatitis. 
We examined the association of one-year post-transplant mortality and EAD with re-
transplantation, pre-transplant serum amino acid profiles, metabolites of tryptophan, 
albumin, neopterin and the severity of diseases (determined by MELD score) and 
post-transplant serum amino acids, metabolites of amino acids, neopterin, CRP and 
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bacterial infections. Proportion of re-transplants was higher in non-survivors and pa-
tients with EAD (Table 1) whereas proportion of patients with hepatic encephalopathy 
was similar in the study groups (Table 1).   
Post-transplant anti-infection prophylaxis included 3 days cefuroxime and 
metronidazole, 3 months cotrimoxazole, 10 days itraconazol, voriconazole or caspo-
fugin. For recipients of CMV-positive donors, oral prophylaxis with valganciclovir was 
performed for a period of 3 months. 
Fifty healthy volunteers (HCs) (24 females, age: mean±SD 40.5±11.2 years) served as 
controls to establish references for the studied parameters such as neopterin,  trypto-
phan, kynurenine, kynurenic acid, quinolinic acid and phenylalanine. Controls were 
free of infectious and other inflammatory illnesses. 
Demographic data including age, gender, original liver diseases, pre-transplant CMV, 
HBV, and HCV IgG status as well as kidney function were similar in survivors and non-
survivors (Table 1). The number of females was significantly higher in patients with 
EAD (Table 1). 
 
Serum Separation 
Serum separator tubes were centrifuged at 4000 rpm for 15 min at 4°C. Serum was 
collected after the blood clotting process. The serum was snap frozen and stored at -
20°C until testing. All serum samples were thawed only once before testing. 
 
Determination of serum phenylalanine, tryptophan and tryptophan metabolites 
(kynurenine, kynurenic acid and quinolinic acid) 
Serum amino acid levels were measured by tandem mass spectrometry. For analysis 
of tryptophan catabolism, heparinized serum samples were drawn from peripheral 
veins in all patients. 100 µL of serum was analysed after addition of 10 μl 
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trichloroacetic acid (50%) (FLUKA, Germany), 60 μl water, 100 µl methanol (JT Baker, 
Deventer, The Netherlands) and 10 μl deuterated standard solutions each 
(phenylalanine (d5-Phe), kynurenine (d6-Kyn) and kynurenic acid (d5-Kyna), 
[Cambridge Isotope Laboratories, Andover, MA, USA]. Respective serum samples 
were mixed, stored at 4°C over night and centrifuged (20,000 g for 15 minutes) after 
thawing. For recording, a Wallac MS2 tandem mass spectrometer (Perkin Elmer, 
Rodgau, Germany) equipped with an electrospray ion source was used. All ions were 
detected in a positive ion mode using multiple reaction monitoring. The first 
quadrupole selected the protonated ions at mass-to-charge ratios (m/z) of 205, 171, 
166, 209, 215, 168, 190 and 195 for Trp, d5-Phe, Phe, Kyn, d6-Kyn, Quin, Kyna and 
d5-Kyna, respectively. Nitrogen was chosen as a collision gas. Fractioned ions m/z 
159 for Trp, 125 for d5-Phe, 120 for Phe, 192 for Kyn, 198 for d6-Kyn, 78 for Quin, 144 
for Kyna and 149 for d5-Kyna were detected in quadrupole Q3 (Q3) (flow solvent: 
0.02% formic acid in 80% aqueous acetonitrile, flow rate 50 μl/min). For quantification, 
serum samples were spiked with standards. Calibration curves were fitted by linear 
least square regression and correlated with the concentration of d5-Trp and d5-Kyna. 
Estimated IDO-activity was assessed as previously reported (18). 
 
Determination of serum neopterin, CRP and albumin 
Serum neopterin was measured with the Neopterin ELISA kit (Brahms, Berlin, 
Germany). Based on control measurements in 70 healthy individuals, serum level of 
>15 nmol/L was considered abnormally high. The protocol provided by the assay 
manufacturer was strictly followed. Serum CRP and albumin were assessed in a certi-
fied laboratory at Heidelberg University Hospital. 
 
Statistical analysis 
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Group comparison was performed using Fisher’s exact test, 2 and Mann-Whitney-U 
test. For all tests, two-sided significance levels of p0.05 after Bonferroni correction 
were considered significant and are bold printed in tables and figures. Univariate 
analysis of variance (ANOVA) for interference analysis and Receiver Operating Char-
acteristic (ROC) curve analyses for determination of diagnostic sensitivity and specific-
ity of parameters were carried out. Data were analyzed using SPSS 18.0 (SPSS Inc., 
Chicago, IL, USA). 
 
Results 
Correlation between MELD score, phenylalanine, tryptophan, tryptophan me-
tabolites, inflammatory markers and serum albumin  
Our results showed that MELD score was positively correlated with phenylalanine 
(r=0.370: p<0.001), tryptophan (r=0.300: p=0.004), kynurenine (r=0.625: p<0.001), 
kynurenic acid (r=0.609: p<0.001), quinolinic acid (r=0.778: p<0.001), 
kynurenine/tryptophan ratio (r=0.544: p<0.001), CRP (r=0.558: p<0.001), neopterin 
(r=0.744: p<0.001), and negatively with albumin (r=-484: p<0.001). Inflammatory 
markers were likewise found to correlate with serum levels of phenylalanine and tryp-
tophan metabolites (kynurenine, kynurenic acid and quinolinic acid): phenylalanine 
was found to be positively correlated with serum levels of CRP (r=0.288: p=0.005), 
neopterin (r=0.441: p<0.001), Kynurenine, kynurenic acid and quinolinic acid corre-
lated positively with CRP (r=0.496, r= 0.418 and r=0.557, respectively: p<0.001) and 
neopterin (r=0.642, r=0.601 and r=0.746, respectively: p<0.001). The results suggest 
an association of MELD score, phenylalanine and tryptophan metabolites with inflam-
mation and immune responses.  
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Increased pre-transplant serum levels of phenylalanine, tryptophan and trypto-
phan-metabolites in patients with ESLD compared to healthy volunteers 
Patients who died during the first year post-transplant due to graft failure or sepsis 
(group-I, n=15) and patients who survived more than one year (group-II, n=74) had 
significantly higher pre-transplant serum levels of phenylalanine, kynurenine, 
kynurenic acid, and a higher kynurenine/tryptophan ratio than HCs (p0.001 for all 
measurements) (Figure 1a, 1b, 1d and 1f). Serum levels of pre-transplant tryptophan 
and quinolinic acid were significantly higher in group-I than in HCs (p0.001 for all 
measurements) and were similar in group-II and HCs (p=0.92 and 0.48, respectively) 
(Figure 1c and 1e). The results indicate increased serum levels of phenylalanine, tryp-
tophan and tryptophan-metabolites in patients with ESLD  
 
Increased pre- and post-transplant serum levels of neopterin, phenylalanine, 
tryptophan and tryptophan metabolites in patients with <one-year vs one-year 
survival  
GI had significantly higher pre-transplant serum levels of phenylalanine, tryptophan, 
kynurenine, kynurenic acid, quinolinic acid and neopterin than GII (p0.005 for all 
measurements) (Figure 1a-c, 1e and 1f). Moreover, group-I had increased MELD 
score and decreased serum albumin as compared to group-II (p0.005 for both inves-
tigations). Survivors had steadily increased serum levels of phenylalanine, metabolites 
of tryptophan and serum bilirubin than non-survivors from pre transplant to day 10 
post-transplant (Figure 2). Serum neopterin from day 5 post-transplant was signifi-
cantly increased in non-survivors and was significantly higher on day 10 than in survi-
vors (p=0.002) (Figure 1). The results suggest that pre- and early post-transplant se-
rum levels of phenylalanine, metabolites of tryptophan and serum neopterin might in-
dicate risk of post-transplant mortality. 
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Sensitivity and specificity of risk factors in the two patients groups 
We performed ROC curve analysis of pre- and post-transplant significant parameters 
to calculate cut-off values. The sensitivity and specificity of all significant parameters 
were calculated and depicted in Table 2. Day 10 post-transplant serum phenylalanine 
>68 µmol/l   showed a sensitivity of 69%, specificity of 93%, positive predictive value 
(PPV) of 56% and negative predictive value (NPV) of 90%. Serum bilirubin >6 mg/dl 
on day 5 post-transplant had a sensitivity of 75%, specificity of 81%, PPV of 46% and 
NPV of 94%. 
 
Regression analysis of significant parameters 
We calculated odds ratios (ORs) and 95% confidence intervals (CIs) to evaluate the 
association between significant parameters and mortality using uni- and multi-variate 
logistic regression models. Univariate regression analyses showed that day 5 post-
transplant serum bilirubin, day 5 and 10 posttransplant phenylalanine and pretrans-
plant serum kynurenine (p<0.001 for all investigations) are most significant associated 
factors of one-year mortality (Table 3). Multivariate regression analysis showed that 
day 10 post-transplant serum phenylalanine > 68 µmol/L (p<0.001: OR=4.045 CI 
1.250-13.095) and day 5 post-transplant serum bilirubin> 6 mg/dl (p=0.005: OR=7.121 
CI 2.263-22.403) are significant associated factors of one-year mortality (Table 3).  
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Discussion 
The aim of this study was to evaluate the pre- and early post-transplant measurement 
of phenylalanine, tryptophan and tryptophan metabolites (kynurenine, kynurenic acid 
and quinolinic acid) in liver transplant recipients in relation to the one-year post-
transplant patient survival. High phenylalanine plasma levels or phenylalanine/tyrosine 
ratios were reported in patients with HIV-1, Dengue fever, HCV, CMV infection (9, 19-
21) and inflammatory responses (15, 22-24). The reason for this phenomenon is un-
clear. However, all these clinical conditions are known to be linked with inflammation 
and immune activation (24). 
IDO degrades the essential amino acid tryptophan into kynurenine and other down-
stream metabolites (13). Acquired immunity is impaired in hemodialysis patients and 
Eleftheriadis et al. suggested that this is the result of increased IDO activity which is 
inducible by inflammation (12). In a new study involving trauma and sepsis patients, 
Ploder et al. showed that, compared to healthy controls, patients exhibited increased 
kynurenine concentrations, kynurenine/tryptophan ratios, and TNF-α, IL-6 and neop-
terin plasma levels (25). Compared to the survivors, the non-survivors showed higher 
concentrations of kynurenine, neopterin, TNF-α and IL-6, as well as a higher 
kynurenine/tryptophan ratio (25). IDO has previously been shown to be associated 
with outcomes of organ transplantation (9, 10, 26-30). Weng et al. indicated that the 
expression of the IDO gene in peripheral blood tightly correlated with the severity of 
acute rejection in a rat liver transplant model (30). Tryptophan metabolites in the 
kynurenine pathway induce immunosuppression (31-34). These results imply that in-
creased tryptophan degradation in patients is due to activated IDO, which most proba-
bly is a consequence of a host defense response. These findings support a possible 
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role of IDO in the development of immunodeficiency that  predisposes  to death in 
transplanted patients (25).  
In this study, we showed for the first time the association of  increased amino acid and 
amino acid metabolites serum levels  with mortality from sepsis and/or graft failure dur-
ing the first year post-transplant. Patients at risk of death showed significantly in-
creased serum levels of phenylalanine and tryptophan metabolites pre- and early post-
transplant. Statistical analysis indicated the closest association of the rate of death 
with pre- and early post-transplant phenylalanine, kynurenine and kynurenic acid se-
rum levels. 
We found the optimal cut-off value of pre-transplant kynurenine at 4. 8 µmol/L, 
kynurenic acid at 1.8 µmol/L and phenylalanine at 70 µmol/L. These cut-off values 
showed a sensitivity and specificity of 68% and 77% for kynurenine, 63% and 73% for 
kynurenic acid and 69% and 70% for phenylalanine for the association with the one 
year post-transplant mortality rate. As expected, post-transplant parameters especially 
phenylalanine and serum bilirubin were stronger associated with one year mortality 
than pre-transplant parameters. 
Prediction of post-transplant mortality following organ transplantation is essential to 
save the patient and the organ, and would initiate more care to rescue patients at risk. 
Sensitivity and specificity of the analyzed parameters were not excellent but accepta-
ble. However, the high negative predictive values (92%, 90%, and 91%, respectively) 
reliably allow the identification of patients likely not to experience mortality. 
As surrogate tests in combination with other parameters such as re-transplantation 
and MELD score, phenylalanine, kynurenine and kynurenic acid help to predict mortal-
ity in liver transplant recipients and may be used as an additional criterion to select 
and allocate patients for transplantation. The combination of pre-transplant phenylala-
nine and tryptophan metabolites with the MELD score substantially enhances outcome 
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prediction of liver transplant recipients and may help to identify subsets of patients that 
are more or less likely to benefit from transplantation. We suggest that pre- and early 
post-transplant measurement of phenylalanine and tryptophan metabolites of the 
kynurenine pathway beside MELD score are very helpful tests to identify patients at 
risk of post-transplant mortality.   
When correlation analyses were performed, phenylalanine, tryptophan and its metabo-
lites correlated with inflammatory markers with the highest correlation for kynurenine, 
kynurenic acid and quinolinic acid. Our results are in agreement with previous findings 
on activation of the tryptophan metabolic pathway by pro-inflammatory stimuli (35-37). 
These results also indicate that liver dysfunction is associated with a strongly activated 
catabolic pathway of tryptophan degradation.  
In summary, disturbance in pre- and early post-transplant metabolism of amino acids 
and their metabolites correlate with one-year mortality rate in liver allograft recipients. 
In conclusion, we have shown that pre-and early post-transplant serum levels of phe-
nylalanine and metabolites of tryptophan are significantly sensitive and specific pa-
rameters with high NPV for post-transplant mortality in liver transplant recipients. 
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Table 1: Demographic and clinical characteristics of the study population 
Parameters non-survivor
 
(n=16) 
survivor 
(n=73) 
EAD+ 
(n=21) 
EAD- 
(n=68) 
age [meanSD years] 52±10 52±11 52±12 53±11 
female gender (n) 5 18 10 13 
Child-pugh category A/BA/C (n) 6/4/6 28/21/24 4/7/10 27/19/22 
donor age [meanSD years] 5916 5718 5618 5519 
anti-viral IgG status 
HBV-Ab+ (n) 1 9 1 9 
HCV-Ab+ (n) 6 16 7 15 
CMV-Ab+ (n) 10 44 18 36 
immunosuppressive drugs 
cyclosporine A (n) 9 41 15 35 
Tacrolimus (n) 5 31 9 27 
Prednisolone (n) 15 72 24 62 
MMF (n) 6 27 9 24 
original liver disease 
congenital/autoimmune/toxic (n) 8 25 10 23 
alcoholic (n) 4 24 8 23 
viral hepatitis (n) 4 24 5 23 
risk factors for EAD and post-transplant mortality 
MELD score (meanSD) 24.3±8.7 17.3±8.1 22.0±9.4 17.0±8.2 
pre-Tx albumin (g/L) 27.0±6.0 32.0±7.0 31.0±7.0 31.0±7.0 
1-10 days post-Tx SIRS (n) 7 17 9 15 
post-Tx bacterial infection (n) 13 37   
re-transplant (n) 8 10 8 10 
pre-Tx bilirubin (mg/dL) 12.9±8.8 7.4±8.6 11.6±10.8 6.9±8.0 
pre-Tx neopterin (nmol/L) 
43.0±27.0
 
(Median=34) 
42.0±67.0
 
(Median=18) 
38.0±34.0 
(Median=33) 
43.0±66.0 
(Median=21) 
pre-Tx creatinine (mg/dL) 1.5±1.0 1.3±1.0 1.4±0.9 1.3±1.0 
pre-Tx CRP (mg/L) 32.0±24.0 21.0±24.0 19.0±18.0 22.0±25.0 
pre-Tx encephalopathy (n) 8 35 10 33 
intra-operative transfusion (n) 29.0±25.0 27.0±22.0 35.0±28.0 24.0±21.0 
rejection (n)  2 9 2 9 
Mann-Whitney U-test, 2 or Fisher exact test were used. p≤0.05,
 
p≤0.01
,  
p≤0.001 
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Table 2: Sensitivity and specificity of significant parameters  
 mortality 
Variables Sensitivity% Specificity% AUC% p 
pre-Tx kynurenine 75 77  77 0.001 
pre-Tx  phenylalanine 69 71  77 0.001 
day 5 post-Tx bilirubin 75 80 77 0.001 
pre-Tx  kynurenic acid 63 76  74 0.002 
day 10 post-Tx neopterin  82 77 81 0.002 
MELD score 75 71 74 0.003 
day 10 post-Tx phenylalanine  69 80 77 0.004 
 day 1 post-Tx phenylalanine 60 79  73 0.005 
 day 1 post-Tx bilirubin 63 75 73 0.005 
day 5 post-Tx kynurenine 73 67 73 0.005 
day 1 post-Tx kynurenic acid 60 82 73 0.006 
pre-Tx qunolinic acid 69 64 72 0.006 
day 5 post-Tx kynurenic acid 60 76 71 0.011 
day 5 post-Tx phenylalanine  68 72 71 0.011 
pre-Tx tryptophan 69 76 70 0.013 
pre-Tx S_albumin 63 63  69 0.019 
early allograft dysfunction 
day 5 post-Tx CRP  61 80 75 <0.001 
day 5 post-Tx kynurenine  70 66 74 0.002 
day 10 post-Tx kynurenine  64 80 77 0.003 
day 1 post-Tx phenylalanine  62 82 71 0.004 
day 3 post-Tx kynurenine  70 67 69 0.009 
day 5 post-Tx phenylalanine  65 72 69 0.017 
MELD score 61 71 66 0.020 
pre-Tx S_kynurenine 61 62  64 0.047 
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Table 3: regression analysis of significant parameters 
Variables exponentiated coef-
ficients 
CI p 
univariate Cox-regression analysis of mortality risk factors 
day 10 post-Tx phenylal.>68 µmol/L 10.812 3.456-33.832 <0.001 
day 5 post-Tx bilirubin>6 mg/dl 10.177 3.270-31.673 <0.001 
day 5 post-Tx phenylal.>84 µmol/L 7.296 2.583-20.609 <0.001 
Re-Tx 4.210 1.838-9.645 0.001 
day 5 post-Tx Kyn/Trp ratios>0.15 5.434 1.533-19.265 0.003 
day 1 post-Tx phenylal.>70 µmol/L 4.471 1.586-12.604 0.004 
pre-Tx Kyn4.0 µmol/L 4.448 1.434-13.799 0.005 
day 1 post-Tx kynurenic acid>3 µmol/L 4.426 1.572-12.463 0.005 
pre-Tx tryptophan>23 µmol/L 4.200 1.525-11.565 0.005 
day 1 post-Tx bilirubin>5 mg/dl 4.025 1.461-11.078 0.006 
day 10 post-Tx neopterin>43 nmol/L 8.781 1.892-40.754 0.006 
pre-Tx  phenylal.70 µmol/L 4.063 1.410-11.706 0.009 
pre-Tx  kynurenic acid1.8 µmol/L 3.480 1.264-9.582 0.014 
day 5 post-Tx kynurenic acid>2 µmol/L 3.415 1.236-9.435 0.018 
pre-Tx qunolinic acid>0.77 µmol/L 3.236 1.124-9.317 0.022 
pre-Tx Kyn/Trp ratios>0.25 3.153 1.174-8.471 0.023 
post-Tx bacteremia  3.428 1.091-10.778 0.024 
day 1 post-Tx Kyn/Trp ratios>0.16 3.178 1.134-8.961 0.028 
day 5 post-Tx kynurenine 3.0 µmol/l 3.070 1.112-8.479 0.030 
MELD score≥20 2.893 1.077-7.772 0.035 
multivariate Cox-regression analysis significant parameters of mortality 
day 10 post-Tx phenylal.>68 µmol/L 13.833 4.007-47.805 <0.0001 
day 1 post-Tx Kyn/Trp ratios>0.16 4.704 1.424-15.554 0.011 
univariate regression analysis of EAD risk factors 
day 1 post-Tx phenylal. ≥ 70 µmol/l 9.652 2.003-31.024 <0.001 
day 5 post-Tx kynurenine 3.0 µmol/l 8.905 2.272-29.075 <0.001 
day 5 post-Tx CRP≥ 27mg/l 6.000 2.708-17.325 0.001 
day 10 post-Tx kynurenine 3.0 µmol/l 9.900 2.240-43.747 0.002 
day 1 post-Tx kynurenine ≥5 µmol/l 6.296 2.0002-19.804 0.002 
day 3 post-Tx phenylal. ≥ 65 µmol/l 4.952 1.554-15.778 0.007 
MELD score ≥20 3.704 1.338-10.255 0.012 
female gender  3.508 1.241-9.908 0.018 
Re-Tx 3.569 1.179-10.801 0.024 
day 3 post-Tx kynurenine 3.5 µmol/l 3.235 1.093-9.576 0.034 
multivariate regression analysis significant parameters of EAD 
day 5 post-Tx kynurenine ≥ 5 µmol/l 6.926 2.236-21.453 0.001 
female gender  5.312 1.455-19.395 0.011 
day 1 post-Tx phenylal. ≥ 70 µmol/l 4.588 1.231-17.099 0.023 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 19 
Figure Legends: 
 
Figure 1a-f: a) phenylalanine, b) kynurenine, c) kynurenic acid, d) quinolinic acid, e) 
neopterin and f) bilirubin at different pre- and posttransplant intervals in survivors (S)  
and non-survivors N.S.). 
 
Figure 2a-e: a) phenylalanine, b) kynurenine, c) CRP, d) bilirubin at different pre- and 
posttransplant intervals in patients with and without EAD. 
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